Statement: Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   English or Spanish speaking women age 18   Heart Rate > 60 bpm   Systolic Blood Pressure > 100 mm/Hg   Deemed eligible to receive neoadjuvant chemotherapy with 12 cycles of weekly taxane therapy (paclitaxel 80mg/m2 or Abraxane 100 mg/m2 if there is a shortage of paclitaxel) followed by 4 cycles of Adriamycin (60mg/m2) and cyclophosphamide (600 mg/m2) given every 2 weeks with growth-factor support.   Echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) with ejection fraction > 50%.   Patients with hormone receptor +/- and human epidermal growth factor receptor 2 protein (HER2) +/- breast cancer are eligible   If a patient has HER2-positive breast cancer, Herceptin and Perjeta will be given along with taxane therapy   Any stage invasive breast cancer provided the primary breast tumor size is  1 cm   Agree to participate in research blood collection at 4 different time periods (20 ml = 4 teaspoons)   Agree to the evaluation of already collected core biopsy, as well as surgical resection tissue, for predictive biomarkers. The biopsy prior to Taxol #1 is optional. Exclusion Criteria:   Patients failing to meet the inclusion criteria   Corrected QT interval (QTc) prolongation as defined by > 470 milliseconds on electrocardiogram (ECG)   First-degree Atrioventricular (AV) block on ECG in which P-R interval lengthened > 200 milliseconds; Second Degree; or Third Degree   On beta-blocker treatment. If discontinued, patients must have been off beta-blockers for at least 3 months.   History of asthma, given concern for β-blockade in this population